Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

WuXi PharmaTech Signs CMO Deal with TaiMed Biologics

publication date: Aug 28, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech signed a contract manufacturing agreement with TaiMed Biologics of Taiwan to manufacture a mAb that was developed to treat HIV. WuXi will make ibalizumab (TMB-355) for the drug’s Phase II and Phase III global clinical trials. Ibalizumab is a viral-entry inhibitor that does not suppress the immune system. WuXi will complete the work at its biologics manufacturing facilities in China and its biologics testing facilities in the US. More details...

Stock Symbol: (NYSE: WX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...